

# Biological PSYCHIATRY

A Journal of Psychiatric Neuroscience and Therapeutics

Volume 57, Number 11, June 1, 2005

## ADVANCING THE NEUROSCIENCE OF ADHD

- 1215 **Attention-Deficit/Hyperactivity Disorder: A Selective Overview**  
*Joseph Biederman*

## COMMENTARY

- 1221 **Toward a New Neuropsychological Model of Attention-Deficit/Hyperactivity Disorder: Subtypes and Multiple Deficits**  
*Bruce F. Pennington*

## ADVANCING THE NEUROSCIENCE OF ADHD

- 1224 **Causal Heterogeneity in Attention-Deficit/ Hyperactivity Disorder: Do We Need Neuropsychologically Impaired Subtypes?**  
*Joel T. Nigg, Erik G. Willcutt, Alysia E. Doyle, and Edmund J.S. Sonuga-Barke*

- 1231 **Causal Models of Attention-Deficit/Hyperactivity Disorder: From Common Simple Deficits to Multiple Developmental Pathways**  
*Edmund J.S. Sonuga-Barke*

- 1239 **Rodent Models of Attention-Deficit/Hyperactivity Disorder**  
*Terje Sagvolden, Vivienne A. Russell, Heidi Aase, Espen Borgå Johansen, and Mehdi Farshbaf*

- 1248 **Modeling Attention-Deficit/Hyperactivity Disorder: A Critical Appraisal of the Cognitive-Energetic Model**  
*Joseph A. Sergeant*

- 1256 **A Developmental Perspective on the Measurement of Cognitive Deficits in Attention-Deficit/Hyperactivity Disorder**  
*Katherine Kipp*

## COMMENTARY

- 1261 **Neuroimaging and Attention-Deficit/Hyperactivity Disorder in the 21st Century: What to Consider and How to Proceed**  
*Scott L. Rauch*

## ADVANCING THE NEUROSCIENCE OF ADHD

- 1263 **Structural Brain Imaging of Attention-Deficit/ Hyperactivity Disorder**  
*Larry J. Seidman, Eve M. Valera, and Nikos Makris*

- 1273 **Functional Neuroimaging of Attention-Deficit/ Hyperactivity Disorder: A Review and Suggested Future Directions**  
*George Bush, Eve M. Valera, and Larry J. Seidman*

- 1285 **The Cognitive Neuroscience of Response Inhibition: Relevance for Genetic Research in Attention-Deficit/Hyperactivity Disorder**  
*Adam R. Aron and Russell A. Poldrack*

- 1293 **In Vivo Neuroreceptor Imaging in Attention-Deficit/Hyperactivity Disorder: A Focus on the Dopamine Transporter**  
*Thomas J. Spencer, Joseph Biederman, Bertha K. Madras, Stephen V. Faraone, Darin D. Dougherty, Ali A. Bonab, and Alan J. Fischman*

- 1301 **Dyslexia (Specific Reading Disability)**  
*Sally E. Shaywitz and Bennett A. Shaywitz*

## COMMENTARY

- 1310 **The Genetics of Attention-Deficit/Hyperactivity Disorder**  
*David L. Pauls*

## ADVANCING THE NEUROSCIENCE OF ADHD

- 1313 **Molecular Genetics of Attention-Deficit/Hyperactivity Disorder**  
*Stephen V. Faraone, Roy H. Perlis, Alysia E. Doyle, Jordan W. Smoller, Jennifer J. Goralnick, Meredith A. Holmgren, and Pamela Sklar*

(continued on next page)

(continued from previous page)

- 1324 Attention-Deficit/Hyperactivity Disorder Endophenotypes**  
*Alysa E. Doyle, Erik G. Willcutt, Larry J. Seidman, Joseph Biederman, Virginie-Anne Chouinard, Julie Silva, and Stephen V. Faraone*
- 1336 Validity of the Executive Function Theory of Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review**  
*Erik G. Willcutt, Alysa E. Doyle, Joel T. Nigg, Stephen V. Faraone, and Bruce F. Pennington*
- 1347 Statistical Approaches to Complex Phenotypes: Evaluating Neuropsychological Endophenotypes for Attention-Deficit/Hyperactivity Disorder**  
*Irwin D. Waldman*
- 1357 Principles of Haplotype Mapping and Potential Applications to Attention-Deficit/Hyperactivity Disorder**  
*Pamela Sklar*
- 1367 Attention-Deficit/Hyperactivity Disorder Pharmacogenomics**  
*James J. McGough*

## COMMENTARY

- 1374 The Neurobiology of Attention-Deficit/Hyperactivity Disorder**  
*Alan J. Fischman and Bertha K. Madras*

## ADVANCING THE NEUROSCIENCE OF ADHD

- 1377 Neurobiology of Executive Functions: Catecholamine Influences on Prefrontal Cortical Functions**  
*Amy F.T. Arnsten and Bao-Ming Li*
- 1385 The Neuropsychopharmacology of Attention-Deficit/Hyperactivity Disorder**  
*Steven R. Pliszka*
- 1391 Stimulant Actions in Rodents: Implications for Attention-Deficit/Hyperactivity Disorder Treatment and Potential Substance Abuse**  
*Ronald Kuczenski and David S. Segal*
- 1397 The Dopamine Transporter and Attention-Deficit/Hyperactivity Disorder**  
*Bertha K. Madras, Gregory M. Miller, and Alan J. Fischman*
- 1410 Imaging the Effects of Methylphenidate on Brain Dopamine: New Model on Its Therapeutic Actions for Attention-Deficit/Hyperactivity Disorder**  
*Nora D. Volkow, Gene-Jack Wang, Joanna S. Fowler, and Yu-Shin Ding*
- 1416 Varieties of Attention-Deficit/Hyperactivity Disorder-Related Intra-Individual Variability**  
*F. Xavier Castellanos, Edmund J.S. Sonuga-Barke, Anouk Scheres, Adriana Di Martino, Christopher Hyde, and Judith R. Walters*

## REVIEWS

- 1424 Neuropsychologic Theory and Findings in Attention-Deficit/Hyperactivity Disorder: The State of the Field and Salient Challenges for the Coming Decade**  
*Joel T. Nigg*
- 1436 Attention-Deficit/Hyperactivity Disorder in a Diverse Culture: Do Research and Clinical Findings Support the Notion of a Cultural Construct for the Disorder?**  
*Luis Augusto Rohde, Cláudia Szobot, Guilherme Polanczyk, Marcelo Schmitz, Silvia Martins, and Silzá Tramontina*

## ORIGINAL ARTICLES

- 1442 Patterns and Predictors of Attention-Deficit/Hyperactivity Disorder Persistence into Adulthood: Results from the National Comorbidity Survey Replication**  
*Ronald C. Kessler, Lenard A. Adler, Russell Barkley, Joseph Biederman, C. Keith Conners, Stephen V. Faraone, Laurence L. Greenhill, Savina Jaeger, Kristina Secnik, Thomas Spencer, T. Bedirhan Üstün, and Alan M. Zaslavsky*
- 1452 Executive Functions and Methylphenidate Response in Subtypes of Attention-Deficit/Hyperactivity Disorder**  
*Gillian A. O'Driscoll, Lana Dépatie, Anne-Lise V. Holahan, Tal Savion-Lemieux, Ronald G. Barr, Claude Jolicoeur, and Virginia I. Douglas*
- 1461 A Family Based Study Implicates Solute Carrier Family 1–Member 3 (SLC1A3) Gene in Attention-Deficit/Hyperactivity Disorder**  
*Darko Turic, Kate Langley, Hywel Williams, Nadine Norton, Nigel M. Williams, Valentina Moskvina, Marianne B. Van den Bree, Michael J. Owen, Anita Thapar, and Michael C. O'Donovan*

**1467 Clinical and Diagnostic Implications of Lifetime Attention-Deficit/Hyperactivity Disorder Comorbidity in Adults with Bipolar Disorder: Data from the First 1000 STEP-BD Participants**

Andrew A. Nierenberg, Sachiko Miyahara, Tom Spencer, Stephen R. Wisniewski, Michael W. Otto, Naomi Simon, Mark H. Pollack, Michael J. Ostacher, Leslie Yan, Rebecca Siegel, and Gary S. Sachs, for the STEP-BD Investigators

**ON THE INTERNET**

**1474 Full Text Or Abstracts of the Following Articles, Which Are Currently "in Press" in *Biological Psychiatry*, Are Available on Our Website Now...**

[www.sobp.org/journal](http://www.sobp.org/journal)

*Biological Psychiatry* (ISSN 0006-3223) is published semi-monthly by Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710. Business Office: 1600 John F. Kennedy Blvd., Suite 1800, Philadelphia, PA 19103-2899. Editorial Office: 360 Park Avenue South, New York, NY 10010-1710. Accounting and Circulation Offices: 6277 Sea Harbor Drive, Orlando, FL 32887-4800. Periodicals postage paid at New York, NY and additional mailing offices.

**Postmaster:** Send address changes to *Biological Psychiatry*, Elsevier Periodicals Department, 6277 Sea Harbor Drive, Orlando, FL 32887-4800. Further information on this journal is available from the Publisher or from this journal's website (<http://www.sobp.org/journal>). Information on other Elsevier products is available through Elsevier's website (<http://www.elsevier.com>).


**Customer Service (orders, claims, online, change of address):** Elsevier Periodicals Customer Service, 6277 Sea Harbor Drive, Orlando, FL 32887-4800. Tel: (800) 654-2452 (U.S. and Canada); (407) 345-4000 (outside U.S. and Canada). Fax: (800) 225-4030 (U.S. and Canada); (407) 363-9661 (outside U.S. and Canada). E-mail: [elspcs@elsevier.com](mailto:elspcs@elsevier.com). Address changes must be submitted four weeks in advance.

**Yearly subscription rates:** United States and possessions: Individual: USD 799; Institution: USD 2174; Student/Resident: USD 162; Single issues USD 84. Same for all other countries (prices include airspeed delivery). To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at the individual rate until proof of status is received. Current prices are in effect for back volumes and back issues.

**Advertising information:** Advertising orders and inquiries can be sent to: **United States, Canada, and South America:** Inez Herrero at Elsevier, 360 Park Avenue South, New York, NY 10010, USA; Tel: (212) 633-3122; Fax (212) 633-3820. Classified advertising orders and inquiries can be sent to Simone Imbert, Elsevier Inc., 360 Park Avenue South, New York, NY 10010, USA; Tel: (212) 462-1908. **Europe and the rest of the world:** Julie Toop; Tel: +44 (0) 1865-843016; Fax: +44 (0) 1865-843976; E-mail: [media@elsevier.com](mailto:media@elsevier.com).

**Author inquiries.** For inquiries relating to the submission of articles, please see Information for Authors, in this issue; please contact the Journal's Editorial Office. Please visit Elsevier's Author Gateway at <http://authors.elsevier.com>. The Author Gateway provides the facility to track accepted articles and set up e-mail alerts to inform you of when an article's status has changed, as well as detailed artwork guidelines, copyright information, frequently asked questions, and more. Contact details for questions arising after acceptance of an article, especially those relating to proofs, are provided after registration of an article for publication.

**Reprints.** For queries about author offprints, e-mail: [authorsupport@elsevier.com](mailto:authorsupport@elsevier.com). To order 100 or more reprints for educational, commercial, or promotional use, contact the Commercial Reprints Department, Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710. Fax: (212) 462-1935; e-mail [reprints@elsevier.com](mailto:reprints@elsevier.com). Reprints of single articles available online may be obtained by purchasing Pay-Per-View access for \$30 per article on the journal website, <http://www.sobp.org/journal>.

 The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper).

© 2005 Society of Biological Psychiatry. All rights reserved.

This journal and the individual contributions contained in it are protected under copyright by the Society of Biological Psychiatry, and the following terms and conditions apply to their use:

**Photocopying.** Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use.

**Permissions** may be sought directly from Elsevier's Rights Department in Philadelphia, PA, USA: phone (215) 239-3804, fax (215) 239-3805, e-mail [healthpermissions@elsevier.com](mailto:healthpermissions@elsevier.com). Requests may also be completed online via the Elsevier homepage (<http://www.elsevier.com/locate/permissions>). In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: (978) 750-8400, fax: (978) 750-4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: (+44) 20 7631 5555; fax: (+44) 20 7631 5500. Other countries may have a local reprographic rights agency for payments.

**Derivative Works.** Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations.

**Electronic Storage or Usage.** Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Rights Department, at the fax and e-mail addresses noted above.

**Notice.** No responsibility is assumed by the publisher or by the Society of Biological Psychiatry for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

*Biological Psychiatry* is cited in *Beck Medical Information*, *Biological Abstracts*, *CABS/Current Awareness in Biological Sciences*, *Chemical Abstracts*, *Current Contents*, *Excerpta Medica*, *Index Medicus*, *Inpharma*, *LMS Alerts Online (DataStar)*, *Mental Health Abstracts*, *Psychological Abstracts*, *Reactions*, *Referativnyi Zhurnal*, *Reference Update*, *Science Citation Index*, and *Selected List of Tables of Contents of Psychiatric Periodicals*.

